José Alvir

6.0k total citations · 1 hit paper
86 papers, 4.3k citations indexed

About

José Alvir is a scholar working on Psychiatry and Mental health, Molecular Biology and Epidemiology. According to data from OpenAlex, José Alvir has authored 86 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Psychiatry and Mental health, 18 papers in Molecular Biology and 14 papers in Epidemiology. Recurrent topics in José Alvir's work include Schizophrenia research and treatment (21 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (14 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). José Alvir is often cited by papers focused on Schizophrenia research and treatment (21 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (14 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). José Alvir collaborates with scholars based in United States, United Kingdom and Italy. José Alvir's co-authors include Jeffrey A. Lieberman, David Mayerhoff, Miranda Chakos, S. Szymanski, Antony Loebel, Stephan Geisler, John M. Kane, A. Koreen, Robert M. Bilder and Margaret G. Woerner and has published in prestigious journals such as Circulation, Blood and PLoS ONE.

In The Last Decade

José Alvir

81 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Duration of psychosis and outcome in first-episode schizophrenia

1992 663 citations Jeffrey A. Lieberman, José Alvir et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
José Alvir United States	26	2.4k	800	673	601	492	86	4.3k
Tamara Arenovich Canada	37	1.6k 0.6×	568 0.7×	572 0.8×	426 0.7×	65 0.1×	64	3.9k
Ralf Pukrop Germany	37	2.1k 0.9×	1.2k 1.6×	913 1.4×	936 1.6×	79 0.2×	82	3.9k
Rafael Tabarés‐Seisdedos Spain	43	4.6k 1.9×	1.0k 1.3×	949 1.4×	294 0.5×	46 0.1×	157	6.5k
Stein Opjordsmoen Norway	53	5.6k 2.3×	3.1k 3.8×	700 1.0×	2.2k 3.6×	105 0.2×	178	8.4k
Jose Ma. J. Alvir United States	21	3.1k 1.3×	1.2k 1.5×	823 1.2×	738 1.2×	42 0.1×	37	4.4k
Antonio Bulbena Spain	29	1.0k 0.4×	493 0.6×	564 0.8×	113 0.2×	138 0.3×	109	2.5k
Majnu John United States	30	982 0.4×	281 0.4×	694 1.0×	172 0.3×	74 0.2×	89	2.5k
Dov Aizenberg Israel	29	1.7k 0.7×	721 0.9×	183 0.3×	170 0.3×	115 0.2×	95	2.7k
Giulia Perini Italy	28	786 0.3×	420 0.5×	240 0.4×	68 0.1×	152 0.3×	66	2.9k
Gavin R. Norton South Africa	46	1.1k 0.5×	2.3k 2.8×	313 0.5×	327 0.5×	404 0.8×	306	7.5k

Countries citing papers authored by José Alvir

Since Specialization

Citations

This map shows the geographic impact of José Alvir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Alvir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Alvir more than expected).

Fields of papers citing papers by José Alvir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José Alvir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Alvir. The network helps show where José Alvir may publish in the future.

Co-authorship network of co-authors of José Alvir

This figure shows the co-authorship network connecting the top 25 collaborators of José Alvir. A scholar is included among the top collaborators of José Alvir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José Alvir. José Alvir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Loftus, Jane, Bradley S. Miller, Craig S. Parzynski, et al.. (2025). A study looking at how missed somatropin injections affect growth in children with growth hormone deficiency: a plain language summary of publication. Therapeutic Advances in Endocrinology and Metabolism. 16. 2455677726–2455677726.

Kemner, Jason E., et al.. (2024). Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx). Cardiology and Therapy. 13(2). 369–378.

Peters, Anthony E., Nicole Solomon, Karen Chiswell, et al.. (2023). Transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: Findings from GWTG-HF. American Heart Journal. 265. 22–30.

Boyd, Lisa M., et al.. (2023). Associations of Community and Individual Social Determinants of Health With Medication Adherence in Patients With Atrial Fibrillation: A Retrospective Cohort Study. Journal of the American Heart Association. 12(8). e026745–e026745. 2 indexed citations

Fukutake, Katsuyuki, et al.. (2023). Real-World Amount of Clotting Factor Concentrates Dispensed and Annual Medical Expenditures for Japanese Patients with Hemophilia B. Journal of Blood Medicine. Volume 14. 649–661.

Loftus, Jane, Bradley S. Miller, Craig S. Parzynski, et al.. (2022). Association of Daily Growth Hormone Injection Adherence and Height Among Children With Growth Hormone Deficiency. Endocrine Practice. 28(6). 565–571. 21 indexed citations

Loftus, Jane, et al.. (2022). Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in the UK. Frontiers in Endocrinology. 13. 1014743–1014743. 4 indexed citations

Chhabra, Amit, Dean Spurden, Patrick F. Fogarty, et al.. (2020). Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagulation & Fibrinolysis. 31(3). 186–192. 25 indexed citations

Nativi-Nicolau, José, et al.. (2020). PCV65 HOSPITALIZATIONS AND MORTALITY AMONG CARDIAC AMYLOIDOSIS PATIENTS COVERED BY MEDICARE ADVANTAGE. Value in Health. 23. S102–S103. 1 indexed citations

10.

Taylor, Peter C., Rieke Alten, Juan J. Gómez‐Reino, et al.. (2018). Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice. Patient Preference and Adherence. Volume 12. 2007–2014. 6 indexed citations

11.

Stewart, Michelle, et al.. (2018). Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers. Neurology and Therapy. 7(2). 349–364. 52 indexed citations

12.

Mundayat, Rajiv, Michelle Stewart, José Alvir, et al.. (2018). Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurology and Therapy. 7(1). 87–101. 25 indexed citations

13.

Taylor, Peter C., Adam Moore, Radu Vasilescu, José Alvir, & M. Tarallo. (2016). A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatology International. 36(5). 685–695. 218 indexed citations

14.

Solem, Caitlyn T., Ahmed Shelbaya, Yin Wan, et al.. (2016). Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data. Neuropsychiatric Disease and Treatment. Volume 12. 2755–2764. 7 indexed citations

15.

Lacey, Loretto, et al.. (2015). Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer’s Disease: Determinants and Level of Changes Observed. Value in Health. 18(5). 638–645. 21 indexed citations

16.

Johnston, Stephen S., et al.. (2014). Characteristics, Treatment, and Health Care Expenditures of Medicare Supplemental-Insured Patients with Painful Diabetic Peripheral Neuropathy, Post-Herpetic Neuralgia, or Fibromyalgia. Pain Medicine. 15(4). 562–576. 13 indexed citations

17.

Berger, Ariel, John Edelsberg, Michael Treglia, José Alvir, & Gerry Oster. (2011). PMH22 CLINICAL AND ECONOMIC CONSEQUENCES OF LONG-TERM USE OF BENZODIAZEPINES IN PATIENTS WITH GENERALIZED ANXIETY DISORDER. Value in Health. 14(3). A189–A189. 1 indexed citations

18.

Wagner, Jan-Samuel, Marco DiBonaventura, Sonali Shah, José Alvir, & Jennifer Whiteley. (2011). PIH32 THE ASSOCIATION OF MENOPAUSAL SYMPTOMS, INCLUDING HOT FLASHES, WITH QUALITY OF LIFE, WORK PRODUCTIVITY AND RESOURCE USE. Value in Health. 14(3). A111–A111. 1 indexed citations

19.

Lieberman, Jeffrey A., Miranda Chakos, José Alvir, et al.. (2001). Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry. 49(6). 487–499. 389 indexed citations

20.

Waltrip, Royce W., Jeffrey Lieberman, Delbert G. Robinson, et al.. (1997). First episode schizophrenia and borna disease virus. Schizophrenia Research. 24(1-2). 261–261. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact